HER2阳性乳腺癌靶向治疗联合化疗疗效显著。然而，耐药可导致治疗失败和疾病进展。长链非编码RNA在影响肿瘤疗效方面作用显著。课题组前期对11对新辅助治疗不同疗效的HER2阳性乳腺癌患者治疗前空心针标本进行转录组测序，筛选差异表达的长链非编码RNA, 通过数据库初筛选定LINC00624作为耐药潜在靶点，并发现LINC00624可通过抑制凋亡增强HER2阳性乳腺癌细胞对化疗及抗HER2治疗药物的耐受。稳转株转录组测序结合差异基因富集分析及细胞实验发现LINC00624可以显著抑制炎症相关基因表达, 提示LINC00624可能通过肿瘤炎症因子途径引发治疗耐药。本课题拟进一步利用临床独立样本验证其疗效预测价值，细胞实验、动物及PDX模型阐明LINC00624及其复合物调控下游信号通路，影响HER2阳性乳腺癌治疗疗效的分子机制，为HER2阳性乳腺癌治疗疗效预测提供新的思路及干预靶点。

Although anti-HER2/neu antibody therapy combined with chemotherapy has achieved an outstanding effect, many patients with HER2 positive breast cancer still succumb to cancer due to therapeutic resistance. Therefore, understanding the mechanisms by which HER2-positive breast cancer develop therapeutic resistance is of vital importance. We have identified differentially expressed lncRNAs by RNA-seq between the pCR and the non-pCR group from HER2 positive patients' core needle biopsy tissue. Survival information was extracted from public database，compared with which LINC00624，a lncRNA has not been reported previously, was selected. We confirmed that high LINC00624 expression is associated with poor overall survival in breast cancer patients. The half maximal inhibitory concentration (IC50) of the chemotherapy drug and anti-HER2 antibody in HER2 positive breast cancer cells was increased by ectopic overexpression of LINC00624. Overexpression of LINC00624 reveals significant inhibition of inflammatory and antigen presentation related genes. LINC00624 probably promotes therapy resistance through anti-tumor immunity inhibition in the tumor microenvironment. However, the detailed mechanism remains unknown. Our further research is to investigate the effect of LINC00624 that exerted on HER2 positive breast cancer therapy, and the precise mechanism LINC00624 and its complex intrigue therapy resistance signaling through cell lines, animal xenografts, and patient-derived xenografts models. Taken together, these studies will provide new insights into the prediction value of LINC00624 which could be a novel therapeutic target for personalized treatment in HER2 positive breast cancer.